Clinical outcomes and safety profile of emicizumab and other treatment options for the management of children and adults with severe haemophilia A in the UAE: A retrospective study at two tertiary hospitals
By:
References
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6 :1–158. doi: 10.1111/hae.14046.
- Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol 2018; 11(11): 835–846. doi: 10.1080/17474086.2018.1531701.
- Kenet G, Fujii T. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence. Haemophilia 2024; 30(2): 267–275. doi: 10.1111/hae.14933.
- US Food & Drug Administration. FDA approves emicizumabkxwh for hemophilia A with or without factor VIII inhibitors [Internet]. FDA; 2019. Available from:
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors (accessed November 2022). - Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–818. doi: 10.1056/NEJMoa1703068.
- Young G, Liesner R, Chang T, S et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134(24): 2127–2138. doi: 10.1182/blood.2019001869.
- Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without Inhibitors. N Engl J Med 2018; 379(9): 811–822. doi: 10.1056/NEJMoa1803550.
- Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6(6): e295–305. doi: 10.1016/S2352-3026(19)30054-7.
- Mancuso ME, Mahlangu J, Sidonio R, et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors – Results from the HAVEN 2 study. Haemophilia 2020; 26(6): 1009–1018. doi: 10.1111/hae.14183.
- Recht M, Neufeld EJ, Sharma VR, , et al. Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the Dosing Observational Study in Hemophilia (DOSE). Value Health 2014;17(6): 744–7448. doi: 10.1016/j.jval.2014.07.003.
- Pollak E, Mühlan H, VON Mackensen S, Bullinger M, Haemo-QoL Group. The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia. Haemophilia 2006; 12(4): 384–392. doi: 10.1111/j.1365-2516.2006.01292.x.
- Von Mackensen S. Quality of life and sports activities in patients with haemophilia. Haemophilia 2007; 13 Suppl 2 :38–43. doi: 10.1111/j.1365-2516.2007.01505.x.
- Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 2016; 25(1): 2–10. doi: 10.1002/pds.3891.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human USE (ICH). Integrated Addendum to ICH E6 (R1): Guideline for good clinical practice E6 (R2). Current Step 4 version. Dated 9 November 2016. Available from
https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf . - Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood 2021; 137(16): 2231–2242. doi: 10.1182/blood.2020009217.
- McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia 2020; 26(4): 631–636. doi: 10.1111/hae.14005.
- Liu G, Huang K, Li G, et al. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China. Front Pediatr 2022; 10: 992267. doi: 10.3389/fped.2022.992267.
- Arcudi S, Gualtierotti R, Marino S, et al. Real-world data on emicizumab prophylaxis in the Milan cohort. Haemophilia 2022; 28(5): e141–144. doi: 10.1111/hae.14630.
- Hahn SM, Han JW, Kim JS, et al. Real-world data for the use of emicizumab in haemophilia A patients with inhibitors – First nationwide report from Korea. Haemophilia 2023; 29(4): 1163–1166. doi: 10.1111/hae.14819.
- Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PloS One 2013; 8(2): e57479. doi: 10.1371/journal.pone.0057479.
- Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C. Rheumatic manifestations of hematologic disorders. Curr Opin Rheumatol 1998; 10(1): 86–90. doi: 10.1097/00002281-199801000-00013.
- Chu WM, Ho HE, Wang JD, et al. Risk of major comorbidities among workers with hemophilia: A 14-year population-based study. Medicine (Baltimore) 2018; 97(6): e9803. doi: 10.1097/MD.0000000000009803.
- Borhany M, Arshad A, Qureshi H, Nadeem R, Jamal A, Ahmed Khan R. Emicizumab prophylaxis in patients with severe hemophilia A: insights from a resource limited country. Clin Appl Thromb Hemost 2024; 30: 10760296231224357. doi: 10.1177/10760296231224357.
- Oladapo AO, Lu M, Walsh S, O’Hara J, Kauf TL. Inhibitor clinical burden of disease: a comparative analysis of the CHESS data. Orphanet J Rare Dis 2018; 13(1): 198. doi: 10.1186/s13023-018-0929-9.
- Mahlangu J, Oldenburg J, Callaghan MU, et al. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia 2019; 25(3): 382–391. doi: 10.1111/hae.13731.
- Wiley RE, Khoury CP, Snihur AWK, et al. From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia 2019; 25(3): 433–440. doi: 10.1111/hae.13754.
- Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY). Res Pract Thromb Haemost 2022; 6(8): e12837. doi: 10.1002/rth2.12837.
- Oka G, Roussel-Robert V, Levivien C, Lopez I, Pieragostini R. Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy. Haemophilia 2023; 29(3): 709–715. doi: 10.1111/hae.14755.
- Skinner MW, Négrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27(5): 854–865. doi: 10.1111/hae.14363.
DOI: https://doi.org/10.2478/jhp-2025-0013 | Journal eISSN: 2055-3390
Language: English
Page range: 104 - 110
Published on: Oct 1, 2025
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Related subjects:
© 2025 Haydar Al Rufaye, Laila Alkhouli, Haytham Al Jabour, Hani Yousif Osman, Muhammad Ibraham Khanani, Muhammad Faisal Khanani, Nasser Al Azein, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.